Table 3.
The relationship between validated ratios, scores and survival in patients undergoing surgery for colon cancer (n = 801)
| Univariate | Multivariate Adjusted for TNM stage | Univariate | Multivariate Adjusted for TNM stage | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| AUC (95% CI) | CSS HR (95% CI) | p value | CSS HR (95% CI) | p value | AUC (95% CI) | OS HR (95% CI) | p value | OS HR (95% CI) | p value | |
| TNM stage | ||||||||||
| I (n = 116) | 0.649 (0.559–0.740) | 0.569 (0.477–0.661) | ||||||||
| II (n = 391) | 4.39 (1.78–10.85) | 0.001 | 1.73 (1.16–2.57) | 0.007 | ||||||
| III (n = 294) | 9.86 (4.02–24.17) | <0.001 | 2.54 (1.70–3.79) | <0.001 | ||||||
| NLR/NLS | ||||||||||
| NLR <3 (n = 388) | 0.577 (0.529–0.624) | 0.594 (0.554–0.633) | ||||||||
| NLR 3–5 (n = 260) | 1.22 (0.87–1.72) | 0.251 | 1.28 (0.91–1.80) | 0.152 | 1.21 (0.95–1.53) | 0.118 | 1.26 (0.99–1.59) | 0.061 | ||
| NLR >5 (n = 153) | 2.06 (1.46–2.92) | <0.001 | 2.11 (1.50–3.00) | <0.001 | 1.85 (1.44–2.37) | <0.001 | 1.88 (1.46–2.42) | <0.001 | ||
| NLS 0 (n = 421) | 0.566 (0.519–0.613) | 0.586 (0.546–0.626) | ||||||||
| NLS 1 (n = 325) | 1.49 (1.10–2.01) | 0.010 | 1.57 (1.16–2.12) | 0.003 | 1.45 (1.17–1.79) | 0.001 | 1.49 (1.21–1.85) | <0.001 | ||
| NLS 2 (n = 55) | 2.01 (1.22–3.30) | 0.006 | 1.85 (1.12–3.05) | 0.016 | 1.68 (1.15–2.46) | 0.007 | 1.59 (1.09–2.33) | 0.016 | ||
| PLR/PLSa | ||||||||||
| PLR ≤150 (n = 237) | 0.538 (0.486–0.589) | 0.555 (0.512–0.598) | ||||||||
| PLR >150 (n = 445) | 1.31 (0.92–1.86) | 0.141 | 1.20 (0.84–1.70) | 0.326 | 1.26 (0.98–1.63) | 0.073 | 1.20 (0.93–1.55) | 0.166 | ||
| PLS 0 (n = 351) | 0.578 (0.525–0.631) | 0.586 (0.542–0.629) | ||||||||
| PLS 1 (n = 283) | 1.39 (0.98–1.96) | 0.061 | 1.33 (0.94–1.88) | 0.106 | 1.34 (1.05–1.70) | 0.020 | 1.29 (1.01–1.65) | 0.040 | ||
| PLS 2 (n = 48) | 2.77 (1.67–4.59) | <0.001 | 2.42 (1.46–4.01) | 0.001 | 2.16 (1.46–3.18) | <0.001 | 1.94 (1.31–2.87) | 0.001 | ||
| LMR/LMSb | ||||||||||
| LMR ≥2.4 (n = 161) | 0.613 (0.539–0.688) | 0.590 (0.528–0.652) | ||||||||
| LMR <2.4 (n = 252) | 2.62 (1.61–4.27) | <0.001 | 2.49 (1.53–4.06) | <0.001 | 2.08 (1.44–3.00) | <0.001 | 1.99 (1.38–2.87) | <0.001 | ||
| LMS 0 (n = 214) | 0.605 (0.528–0.681) | 0.585 (0.522–0.648) | ||||||||
| LMS 1 (n = 169) | 1.69 (0.99–2.86) | 0.051 | 1.65 (0.97–2.81) | 0.064 | 1.47 (0.99–2.17) | 0.058 | 1.41 (0.95–2.10) | 0.088 | ||
| LMS 2 (n = 30) | 3.68 (1.81–7.49) | <0.001 | 3.67 (1.80–7.49) | <0.001 | 2.81 (1.59–4.95) | <0.001 | 2.76 (1.56–4.88) | <0.001 | ||
| NPSa | ||||||||||
| NPS 0 (n = 491) | 0.580 (0.526–0.634) | 0.576 (0.532–0.619) | ||||||||
| NPS 1 (n = 140) | 1.76 (1.22–2.55) | 0.003 | 1.47 (1.02–2.13) | 0.042 | 1.64 (1.26–2.14) | <0.001 | 1.47 (1.12–1.92) | 0.005 | ||
| NPS 2 (n = 51) | 2.50 (1.52–4.10) | <0.001 | 2.14 (1.30–3.51) | 0.003 | 1.83 (1.24–2.70) | 0.002 | 1.65 (1.12–2.44) | 0.011 | ||
| CAR/mGPS | ||||||||||
| CAR ≤0.22 (n = 412) | 0.582 (0.536–0.628) | 0.603 (0.563–0.642) | ||||||||
| CAR >0.22 (n = 389) | 1.88 (1.40–2.51) | <0.001 | 1.76 (1.31–2.35) | <0.001 | 1.88 (1.53–2.31) | <0.001 | 1.84 (1.49–2.26) | <0.001 | ||
| mGPS 0 (n = 474) | 0.591 (0.544–0.639) | 0.623 (0.582–0.663) | ||||||||
| mGPS 1 (n = 173) | 1.35 (0.95–1.94) | 0.099 | 1.22 (0.85–1.75) | 0.282 | 1.49 (1.17–1.90) | 0.001 | 1.44 (1.12–1.84) | 0.004 | ||
| mGPS 2 (n = 154) | 2.47 (1.77–3.46) | <0.001 | 2.31 (1.65–3.25) | <0.001 | 2.32 (1.81–2.99) | <0.001 | 2.28 (1.76–2.95) | <0.001 | ||
an = 682.
bn = 413.
AUC area under the curve, CI confidence interval, HR hazard ratio, CSS cancer-specific survival, OS overall survival, TNM tumour node metastasis, NLR neutrophil–lymphocyte ratio, NLS neutrophil–lymphocyte score, CAR C-reactive protein albumin ratio, mGPS modified Glasgow prognostic score, NPS neutrophil–platelet score, LMS lymphocyte–monocyte score, LMR lymphocyte–monocyte ratio, PLR platelet–lymphocyte ratio, PLS platelet–lymphocyte score